Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
Clinical trial NCT04624906 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04624906
- Sponsor
- Sunnybrook Health Sciences Centre
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-02
- Primary completion
- 2025-12-31
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.